MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause

MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause

MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flus…

HM GovernmentSource

Previus Post
Statement to
Next Post
Recovered appeal:

Leave a comment